Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af MACI hos patienter i alderen 10 til 17 år med symptomatiske chondrale eller osteochondrale defekter i knæet (PEAK)

30. oktober 2026 opdateret af: Vericel Corporation

Et prospektivt, åbent, randomiseret, samtidig aktivt kontrolleret, longitudinalt, multicenter, fase 3 klinisk undersøgelse af sikkerheden og effektiviteten af ​​MACI hos patienter i alderen 10 til 17 år med symptomatiske chondrale eller osteochondrale defekter i knæet på grund af osteochondritis dissecan. Akut Traume

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 participants, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).

After meeting screening criteria at the initial visit, all participants will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, participants will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All participants who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible participants will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Participants randomized to microfracture will undergo the procedure during the screening arthroscopy.

All biopsied tissue will be sent to the Vericel manufacturing facility in Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from participants randomized to the MACI group will be used in the preparation of the MACI implant; cells from participants randomized to the microfracture group will be cryopreserved.

Participants randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Participants are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.

Participants will be followed post-study treatment for 2 years (104 Weeks).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

45

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • Palo Alto, California, Forenede Stater, 94304
        • Rekruttering
        • Stanford University School of Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Kevin Shea
      • Sacramento, California, Forenede Stater, 95817
        • Rekruttering
        • Shriners Hospital for Children Northern California
        • Ledende efterforsker:
          • Brian Haus
        • Kontakt:
      • Sacramento, California, Forenede Stater, 95817
        • Rekruttering
        • University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
        • Ledende efterforsker:
          • Brian Haus
        • Kontakt:
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70121
        • Rekruttering
        • Ochsner Health System-Elmwood
        • Kontakt:
        • Ledende efterforsker:
          • Brian Godshaw
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21224
        • Rekruttering
        • Johns Hopkins Hospital
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Rushyuan Jay Lee
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48106
        • Rekruttering
        • University of Michigan Medsport Orthopaedic Surgery
        • Kontakt:
        • Ledende efterforsker:
          • Eileen Crawford
    • New York
      • The Bronx, New York, Forenede Stater, 10467
        • Afsluttet
        • Montefiore Medical Center/Albert Einstein College of Medicine
    • Ohio
      • Akron, Ohio, Forenede Stater, 44308
        • Rekruttering
        • Akron Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • John Polousky
      • Columbus, Ohio, Forenede Stater, 43202
        • Rekruttering
        • The Ohio State University Jameson Crane Sports Medicine Institute
        • Kontakt:
        • Ledende efterforsker:
          • Christopher Kaeding
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Penn Medicine University City
        • Kontakt:
        • Ledende efterforsker:
          • James Carey
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
        • Kontakt:
        • Ledende efterforsker:
          • Theodore Ganley
    • Rhode Island
      • East Providence, Rhode Island, Forenede Stater, 02914
        • Rekruttering
        • University Orthopedics, Inc.
        • Kontakt:
        • Ledende efterforsker:
          • Nicholas Lemme
    • Texas
      • Houston, Texas, Forenede Stater, 77094
        • Afsluttet
        • Texas' Children Hospital
      • Plano, Texas, Forenede Stater, 75024
        • Afsluttet
        • Children's Medical Center Plano
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53201
        • Rekruttering
        • Children's Hospital of Wisconsin
        • Kontakt:
        • Ledende efterforsker:
          • John Erickson

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

10 år til 17 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 10 to 17 years at the time of planned randomization

  • Symptomatic cartilage or osteochondral defects

  • One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).

    1. Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
    2. Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
  • At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.

  • Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.

  • Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.

  • Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.

  • Written informed consent

Exclusion Criteria:

  • Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)

  • Previous investigational drug or device use within 3 months prior to Screening

  • Avascular necrosis of the target knee (other than potential OCD lesion to be treated)

  • Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate

  • ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion

  • Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)

  • Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint

  • Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)

  • Known history of septic arthritis in the index knee joint

  • Current malignancy or treatment for malignancy within the past 5 years

  • Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin

  • Females who are pregnant or lactating

  • Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:

    • Any condition that has potential for negatively impacting intra or postoperative course
    • Conditions that limit compliance with rehabilitation program
    • Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
    • Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
    • Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: MACI

autologous cultured chondrocytes on porcine collagen membrane

autologous cultured chondrocytes on porcine collagen membrane

Andet: microfracture

surgical procedure

Arthroscopic microfracture treatment

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
Tidsramme: Baseline and Week 104

A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 104

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change from Baseline in KOOS-Child subscores
Tidsramme: Baseline and Week 104

The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 104
Change from Baseline in KOOS-Child subscores
Tidsramme: Baseline and Week 52

The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL).

Baseline and Week 52

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Treatment Emergent Adverse Events
Tidsramme: Week 104

A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

Week 104

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Jonathan Hopper, BSc (Hons), MB ChB, FRCSEd, Vericel Corporation

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. oktober 2018

Primær færdiggørelse (Anslået)

1. februar 2030

Studieafslutning (Anslået)

1. februar 2030

Datoer for studieregistrering

Først indsendt

4. april 2018

Først indsendt, der opfyldte QC-kriterier

15. juli 2018

Først opslået (Faktiske)

17. juli 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • 55-1702-1

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .